BiotechTube

GFH925

Phase 1/2Completed
0 watching 0 views this week⚡ Active
40
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

KRAS G12C

Conditions

KRAS G12C

Trial Timeline

Sep 13, 2021 → Dec 20, 2024

NCT ID
NCT05005234

About GFH925

GFH925 is a phase 1/2 stage product being developed by Innovent Biologics for KRAS G12C. The current trial status is completed. This product is registered under clinical trial identifier NCT05005234. Target conditions include KRAS G12C.

Hype Score Breakdown

Clinical
13
Activity
8
Company
9
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05005234Phase 1/2Completed

Competing Products

20 competing products in KRAS G12C

See all competitors
ProductCompanyStageHype Score
HRS-4642 + Adebrelimab + SHR-9839 + Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection + Cetuximab Solution for InfusionJiangsu Hengrui MedicinePhase 1/2
41
HRS-6093Jiangsu Hengrui MedicinePhase 1
33
HRS-4642Jiangsu Hengrui MedicinePhase 1
33
HRS-4642 + AG + HRS-4642 placebo + AGJiangsu Hengrui MedicinePhase 3
77
Pembrolizumab + TrametinibMerckPhase 1
33
Opnurasib + TNO155 + trametinib + cetuximab + tislelizumabNovartisPhase 1/2
41
JDQ443 + TNO155 + tislelizumabNovartisPhase 1/2
41
JDQ443 + trametinib + Ribociclib + cetuximabNovartisPhase 1/2
41
JDQ443NovartisPhase 2
52
Trametinib + Anlotinib + TislelizumabNovartisPhase 1/2
41
AMG 510AmgenPhase 1
32
AMG 510 + DocetaxelAmgenPhase 3
76
Epirubicine, Oxaliplatin, Capecitabine, PanitumumabAmgenPhase 2
51
AMG 410 + Pembrolizumab + PanitumumabAmgenPhase 1
32
sotorasib + Anti PD-1/L1 + MidazolamAmgenPhase 1/2
40
MEK162 and mFOLFIRIPfizerPhase 1
32
IBI351+AK112Innovent BiologicsPhase 2
51
Momelotinib (MMB) + TrametinibGSK plcPhase 1
32
BAY3498264BayerPhase 1
30
ARV-806ArvinasPhase 1/2
36

Other Products from Innovent Biologics

Taxane and Carboplatin + Short-term SintilimabApproved
84
Teprotumumab N01 + MethylprednisoloneApproved
84
IBI311Phase 3
76
Febuxostat + TigulixostatPhase 3
76
IBI301 plus CHOP + Rituximab plus CHOPPhase 3
76